Windlas Biotech Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/f4zq0ca4a021mdq7p8u08qeq.pdf

Key Takeaways


Injectable Facility: The Next Growth Cycle

Hitesh Windlas: "Since the injectables are sterile products that are put into the body directly, there is a huge amount of qualification work that goes on after the injectable. This is called as media fill and validation. This can take anywhere from four to six months. If you are lucky and everything happens in the first shot, it can be four months or if it is outer side, I would say six months."

Trade Generics: The Standout Performer

Hitesh Windlas: "We are working with almost 600-700 stockists directly across India. And we are able to do it because of the way we have built our IT system."

CDMO: The Steady Anchor

Hitesh Windlas: "In the last 21 years history of the company in CDMO, we might have said no to a customer because it doesn't work for us, it doesn't meet our ability to support them. But, we have never lost a customer."

Exports: A Back-Ended Bet on ROW

Hitesh Windlas: "The ROW space is a different space. And in the rest of the world, which between Southeast Asia, Africa, CIS, Middle East and so on, this space does not have very large batch sizes. And the number of SKUs required to serve a country with small batch sizes is very high. So, it has a natural advantage for a CMO player like us, which are used to manufacturing a very large variety of SKUs." [9–10]

Margins & Capital Allocation

Komal Gupta: "In case we are able to catch up through trade generics and export verticals for the overall number that we are talking about for four years, we would be happier in that sense because they are better profitability and better control verticals for us."

Guidance & Commitments

CommitmentSpecificsTimeline
Injectable facility mechanical completionConstruction complete, ready for qualificationEnd of Q2 FY24
Injectable facility first commercial batchesPost media fill and validation (4–6 months)Within FY24
Injectable facility major revenue contributionMaterial top-line impact beginsFY25 onward
Injectable facility EBITDA margin18–20% at optimal utilization (55–60%)At optimal capacity
Long-term segment targets (from FY21 base)Double CDMO, triple trade generics, quadruple exports~4 years from current (delayed ~1 year from original 5-year target)
Oral solids capacity ceilingCurrent facility supports up to ~₹600 crores revenue; expansion readiness may be neededNo major capex in FY24; possible expansion readiness by end of FY24

Key Metrics

MetricQ4 FY23
Consolidated revenue₹140.7 crores
Consolidated EBITDA₹16.4 crores
Consolidated PAT₹11.4 crores
Gross margin36.8%, up 191 bps YoY
EBITDA margin11.7%, up 40 bps YoY
CDMO vertical revenue₹110.4 crores, up 14% YoY; 78% of consolidated revenue
Trade generics and institutional vertical revenue₹22 crores, up 50% YoY; 16% of consolidated revenue
Exports vertical revenue₹7 crores, down 26% YoY; 5% of consolidated revenue
FY23 consolidated revenue₹513.1 crores, up 10% YoY
FY23 consolidated EBITDA₹60.2 crores, up 15% YoY
FY23 consolidated PAT₹42.6 crores, up 12% YoY
FY23 gross margin36.6%, up 160 bps YoY
FY23 EBITDA margin11.7%, up 50 bps YoY
Net cash flow from operations (FY23)₹61 crores
Liquidity position (end of FY23)₹138 crores
Top 10 customer concentrationBelow 50% of total revenue
CDMO market share~1% (per DRHP-era study)
Injectable facility investment~₹50 crores; expected asset turnover ~1.3x, targeting ₹70–₹80 crores revenue
Oral solids facility capacity~₹600 crores revenue supportable
Trade generics long-term growth targetTriple from FY21 base, on track to potentially exceed
CDMO long-term growth targetDouble from FY21 base
Exports long-term growth targetQuadruple from FY21 base